| P50 | author | Kenneth C. Anderson | Q28421846 |
| | Paul G. Richardson | Q87712102 |
| | Jacob P Laubach | Q87769541 |
| | Robert Schlossman | Q114300414 |
| | Constantine S Mitsiades | Q117224720 |
| P2860 | cites work | Thalidomide is an inhibitor of angiogenesis | Q24563363 |
| | Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications | Q24685895 |
| | Cancer statistics, 2008 | Q27860585 |
| | Thalidomide therapy and deep venous thrombosis in multiple myeloma | Q28193919 |
| | Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group | Q28207984 |
| | Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network | Q28220911 |
| | Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial | Q28252396 |
| | Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial | Q30433139 |
| | Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma | Q33367821 |
| | Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma | Q33369909 |
| | Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma | Q33377526 |
| | Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma | Q33386052 |
| | Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma | Q33389111 |
| | Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma | Q34401962 |
| | International staging system for multiple myeloma | Q34408882 |
| | NF-kappa B as a therapeutic target in multiple myeloma | Q34521393 |
| | Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America | Q34585268 |
| | Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma | Q34815786 |
| | Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy | Q35848356 |
| | Adverse effects of thalidomide administration in patients with neoplastic diseases | Q35909155 |
| | Improved survival in multiple myeloma and the impact of novel therapies | Q36478461 |
| | Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma | Q36624286 |
| | Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma | Q36765107 |
| | New drugs for myeloma | Q36865500 |
| | Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature | Q36892610 |
| | Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma | Q37031246 |
| | Thalidomide for treatment of multiple myeloma: 10 years later | Q37075738 |
| | Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy | Q37280739 |
| | Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma | Q37523265 |
| | International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). | Q37530452 |
| | Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens | Q37533983 |
| | Importance of achieving a complete response in multiple myeloma, and the impact of novel agents | Q37729617 |
| | Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma | Q40201943 |
| | Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide. | Q40450178 |
| | Thalidomide-induced sinus bradycardia | Q42166156 |
| | Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. | Q42914716 |
| | Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study | Q43048164 |
| | Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial | Q43109172 |
| | Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma | Q43648034 |
| | Hypothyroidism in patients with multiple myeloma following treatment with thalidomide | Q43923739 |
| | Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications | Q44010411 |
| | The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma | Q44177889 |
| | Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. | Q44189620 |
| | The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications | Q44211035 |
| | Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma | Q44323252 |
| | Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma | Q44662272 |
| | Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity | Q44971172 |
| | Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma | Q44975171 |
| | Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. | Q46006794 |
| | Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. | Q46068547 |
| | Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure | Q46094234 |
| | Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma | Q46291462 |
| | Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro | Q46409873 |
| | Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma | Q46505738 |
| | Azotemia associated with use of lenalidomide in plasma cell dyscrasias | Q46615368 |
| | Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. | Q46793597 |
| | Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group | Q46859424 |
| | Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients | Q46886126 |
| | Lenalidomide-induced severe hepatotoxicity | Q46913468 |
| | Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma | Q46972453 |
| | Thalidomide and hematopoietic-cell transplantation for multiple myeloma | Q46981475 |
| | Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial | Q46985882 |
| | Bortezomib inhibits human osteoclastogenesis. | Q52925512 |
| | Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. | Q53243787 |
| | Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma. | Q53470786 |
| | A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy | Q58050810 |
| P433 | issue | 1 | |
| P921 | main subject | thalidomide | Q203174 |
| P304 | page(s) | 51-60 | |
| P577 | publication date | 2011-02-01 | |
| P1433 | published in | Expert Review of Hematology | Q15734429 |
| P1476 | title | Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma | |
| P478 | volume | 4 | |